ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADC Therapeutics SA (ADCT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its financial performance is weighed down by significant net income and EPS declines. The technical indicators are neutral, and there are no strong positive catalysts or trading signals to suggest immediate upside potential. A hold position is recommended until stronger signals or catalysts emerge.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 41.33, and moving averages are converging, suggesting no clear trend. The stock is trading near its S1 support level of 3.868, with resistance at 4.143. Overall, the technical indicators do not signal a strong buying opportunity.
Revenue increased by 36.36% YoY in the latest quarter, and gross margin improved slightly to 92.63%. Analyst Robert Burns raised the price target to $8 and maintained a Buy rating.
Net income dropped significantly by -79.14% YoY, and EPS declined by -86.21% YoY. No recent news or significant insider or hedge fund activity. The stock has a high implied volatility of 259.57%, indicating potential risk.
In Q4 2025, revenue grew to $23.06M, up 36.36% YoY. However, net income dropped to -$6.41M, a decline of -79.14% YoY, and EPS fell to -0.04, down -86.21% YoY. Gross margin improved slightly to 92.63%.
H.C. Wainwright analyst Robert Burns raised the price target to $8 from $7 and maintained a Buy rating. This reflects optimism but is not supported by strong financial or technical performance.
